Enrico Morera

Enrico Morera

Auto-generated profile, based on publicly available information

Enrico Morera

Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, piazzale Aldo Moro 5, 00185 Roma, Italy

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1985 in Tetrahedron Letters
Verified
Journal Article
Closed access
SCSandro Cacchi
Sandro Cacchi
EMEnrico Morera
Enrico Morera
GOGiorgio Ortar
Giorgio Ortar

1 January 1986 in Tetrahedron Letters
Verified
Journal Article
Closed access
SCSandro Cacchi
Sandro Cacchi
PCPier Giuseppe Ciattini
Pier Giuseppe Ciattini
EMEnrico Morera
Enrico Morera
GOGiorgio Ortar
Giorgio Ortar

1 January 1984 in Tetrahedron Letters
Verified
Journal Article
Closed access
SCSandro Cacchi
Sandro Cacchi
EMEnrico Morera
Enrico Morera
GOGiorgio Ortar
Giorgio Ortar

1 January 1986 in Tetrahedron Letters
Verified
Journal Article
Closed access
SCSandro Cacchi
Sandro Cacchi
PCPier Giuseppe Ciattini
Pier Giuseppe Ciattini
EMEnrico Morera
Enrico Morera
GOGiorgio Ortar
Giorgio Ortar

1 May 2003 in Biochemical Pharmacology
Verified
Journal Article
Closed access
GOGiorgio Ortar
Giorgio Ortar
ALAlessia Ligresti
Alessia Ligresti
LPLuciano De Petrocellis
Luciano De Petrocellis
EMEnrico Morera
Enrico Morera
Vincenzo Di MarzoVincenzo Di Marzo
Vincenzo Di Marzo

15 May 2004 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
ALAlessia Ligresti
Alessia Ligresti
EMEnrico Morera
Enrico Morera
MSMario van der Stelt
Mario van der Stelt
KMKrisztina Monory
Krisztina Monory
BLBeat Lutz
Beat Lutz
Vincenzo Di MarzoVincenzo Di Marzo
Vincenzo Di Marzo
Indirect evidence for the existence of a specific protein-mediated process for the cellular uptake of endocannabinoids has been reported, but recent results suggested that such a process, at least for AEA [N-arachidonoylethanolamine (anandamide)], is facilitated uniquely by its intracellular hydrolysis by FAAH (fatty acid amide hydrolase) [Glaser, Abumrad, Fatade, Kaczocha, Studholme and Deutsch (2003) Proc. Natl. Acad. Sci. U.S.A. 100, 4269–4274]. In the present study, we show that FAAH alone cannot account for the facilitated diffusion of AEA across the cell membrane. In particular, (i) using a short incubation time (90 s) to avoid AEA hydrolysis by FAAH, AEA accumulation into rat basophilic leukaemia or C6 cells was saturable at low µM concentrations of substrate and non-saturable at higher concentrations; (ii) time-dependent and, at low µM concentrations of substrate, saturable AEA accumulation was observed also using mouse brain synaptosomes; (iii) using synaptosomes prepared from FAAH-deficient mice, saturable AEA accumulation was still observed, although with a lower efficacy; (iv) when 36 AEA and N-oleoylethanolamine analogues, most of which with phenyl rings in the polar head group region, were tested as inhibitors of AEA cellular uptake, strict structural and stereochemical requirements were needed to observe significant inhibition, and in no case the inhibition of FAAH overlapped with the inhibition of AEA uptake; and (v) AEA biosynthesis by cells and sensory neurons was followed by AEA release, and this latter process, which cannot be facilitated by FAAH, was still blocked by an inhibitor of AEA uptake. We suggest that at least one protein different from FAAH is required to facilitate AEA transport across the plasma membrane in a selective and bi-directional way.